Eli Lilly: latest news - GoINPHARMA
Wednesday, 26 September 2018 - 2:07

Eli Lilly

New therapies preventing migraine episodes to be launched

US-based drugmaker Eli Lilly & Co. on Friday announced that EMA has recommended the marketing approval in Europe for its monoclonal antibody Emgality (galcanezumab). Emgality has already been granted conditional approval in the US by FDA. It is part of…

Eli Lilly expects to raise at least $1.45bn from Elanco IPO

The US-based group Eli Lilly expects to raise at least $1.45bn by listing 20% of its Elanco division (Animal Health business), that is approximately 63 million shares at a price between $20 and $23 per share. The decision to list…

Eli Lilly decides to list Elanco Animal Health division

US-based pharmaceutical group Eli Lilly has announced today in a press release that it has completed its strategic review of Elanco Animal Health. After 8 months, the Indianapolis-headquartered company has decided to list an ownership stake of less than 20…

Unstoppable Eli Lilly: AurKa Pharma acquired for $575m

US-based pharmaceutical group Eli Lilly seems unstoppable in M&A–after informing on Thursday that it had acquired Armo Bioscience for $1.6bn, it has announced today a new deal. Indeed, shortly before Wall Street opened, the Indianapolis-based group announced it has acquired…

Positive first quarter for Eli Lilly, diabetes +30%

US-based drugmaker Eli Lilly posted today, before Wall Street opened, its Q1 2018 results. These were consistent with analysts’ and investors’ expectations–indeed, Eli Lilly’s share price had just a slight variation. The group’s sales volume increased by 9% ($5.7bn), while…

Eli Lilly keeps momentum: new approval for Verzenio

Eli Lilly maintains momentum: FDA has approved Verzenio (abemaciclib)  in combination with an aromatase inhibitor (AI) for the treatment of some breast cancer types. The approval reflects the positive results from the Phase III MONARCH 3 trial, which has demonstrated…

Positive fourth quarter for Eli Lilly, shares rise

US-based pharmaceutical group Eli Lilly has reported today its Q4 2017 results, which are beyond analyst’s expectations. The company has posted sales of $6.16bn, a 7% increase vs Q4 2016, while analysts expected 6.5%. Diabetes treatment Trulicity remains the top-selling…

US groups stronger and more competitive thanks to fiscal reform

The JP Morgan Healthcare Conference, which has just ended in San Francisco, has given analysts an opportunity to analyze the different views of big pharma companies’ CEOs . The fiscal reform proposed by the Trump administration has been a widely-debated…

Large pharma groups increasingly move away from Animal Health business

Large pharmaceutical groups have clearly lost interest in drugs for animals and analysts familiar with the business were not surprised as Eli Lilly–similarly to other drugmakers–announced it is looking for a strategic solution for its  Elanco (Animal Health) business.  Pfizer…

Eli Lilly signs $1.7bn agreement with Germany’s CureVac

Eli Lilly has invested €45m in equities in Tubingen, Germany-based CureVac, in order to fund the development of 5 cancer vaccines. As part of the agreement, Eli Lilly will make CureVac an upfront payment of $50m so as to support…

Eli Lilly’s Verzenio, new breast cancer therapy, approved

FDA approved yesterday afternoon Eli Lilly’s abemaciclib, an investigational treatment for HR-positive, advanced breast cancer, which accounts for 72% of breast cancer cases. The new therapy will be marketed as Verzenio and launched on the US market as of mid…

Dramatic announcement by Eli Lilly: 3,500 cuts worldwide

US-based pharmaceutical group Eli Lilly announced today in a press release a cost reduction plan that will lead to cutting 8% of its staff. Most dismissals will come from the US, where 2,000 jobs will be cut, while the remaining…

Fast Track designation granted to Pfizer/Eli Lilly’s tanezumab

FDA granted accelerated approval pathway to the new painkiller tanezumab, by Pfizer and Eli Lilly, which acts in a less dangerous manner than opioids. Should tanezumab be approved, it would be the first-in-class non-opioid painkiller for the treatment of chronic…

Eli Lilly to create hundreds of jobs in Cork

US-based group Eli Lilly announced a €200m investment to expand Cork production site (Ireland). The expansion project will create hundreds of new jobs, in addition to the 500 workers already employed at the site, which manufactures biologic drugs. The works…

Eli Lilly acquires CoLucid Pharmaceuticals for $960m

Eli Lilly announced today before Wall Street opened that it has acquired CoLucid Pharmaceuticals for $960m. The price corresponds to $46.5 per share, that is to say that Eli Lilly has paid a 33% premium to CoLucid Pharmaceuticals’ closing price…

The pipelines of the groups working on Alzheimer’s treatments

Following the recently announced failure of Eli Lilly’s clinical trial, many analysts are drawing up new rankings of the pipelines of the most active groups in the Alzheimer’s treatment area. Germany-based biotech Probiodrug is focused on a research branch aimed…

Express Scripts to collaborate with Lilly to control insulins costs

Eli Lilly and Express Scripts are collaborating in order to offer interesting discounts on some diabetes treatments. The discounted prices will apply as of 1 January 2017 and will cover especially Humalog and Humulin, but also the Lantus follow-on biologic…

Lilly/AstraZeneca deal for Alzheimer’s treatment

Eli Lilly and AstraZeneca announced a worldwide agreement to co-develop MEDI1814, an antibody selective for amyloid-beta 42 (Aβ42). The product is currently in Phase I development as a potential DMT (disease-modifying treatment) for Alzheimer’s disease. MEDI1814 binds selectively to Aβ42,…

Positive quarter for Eli Lilly, yet results do not meet expectations

Ely Lilly’s shares (Wall Street) lost nearly 3% yesterday, when stock markets opened, soon after announcing its third-quarter results. The Indianapolis-based group’s performance has not met analysts’ predictions and the management have lowered their expectations for the current year. Such…

Expert sees good chances of success for Lilly’s Alzheimer’s drug

Analysts from BMO have examined the chances of success for a drug currently tested in Alzheimer’s disease and in advanced-stage clinical development – Eli Lilly’s solanezumab. They have made reference to evaluations by one of the leading Alzheimer’s disease experts,…